InsidersTradesSigma
Track the 瑞普生物 stock price and the full directors' dealings record of the company, a listed issuer based in China. Shares are quoted on the CN market, under the supervision of SSE / SZSE (CSRC). Operating in the Health Care sector, 瑞普生物 has recorded 2 public disclosures. Market capitalisation: €8.5bn. The latest transaction was reported on 16 June 2026 (Purchase). Among the most active insiders: 徐雷. The full history is accessible without an account.
Analysts rate 瑞普生物 Buy (bullish), based on 3 analysts. Average price target: CN¥20.41.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
瑞普生物 is a company focused on the health and pharmaceutical sector, specializing in the research and development of biopharmaceutical solutions. It is listed on the XSHE market.